アポリポプロテインE

APOE
PDBに登録されている構造
PDB	オルソログ検索: RCSB PDBe PDBj
PDBのIDコード一覧
	1B68, 1BZ4, 1EA8, 1GS9, 1H7I, 1LE2, 1LE4, 1LPE, 1NFN, 1NFO, 1OEF, 1OEG, 1OR2, 1OR3, 2KC3, 2KNY, 2L7B
識別子
記号	APOE, AD2, APO-E, LDLCQ5, LPG, apolipoprotein E, ApoE4
外部ID	OMIM: 107741 MGI: 88057 HomoloGene: 30951 GeneCards: APOE
遺伝子の位置 (ヒト)
染色体	19番染色体 (ヒト)
終点	44,909,393 bp
遺伝子の位置 (マウス)
染色体	7番染色体 (マウス)
終点	19,433,113 bp
RNA発現パターン
	さらなる参照発現データ
遺伝子オントロジー
分子機能	• heparin binding; • very-low-density lipoprotein particle receptor binding; • low-density lipoprotein particle receptor binding; • lipoprotein particle binding; • phosphatidylcholine-sterol O-acyltransferase activator activity; • phospholipid binding; • cholesterol transfer activity; • protein homodimerization activity; • アミロイドβ結合; • 血漿タンパク結合; • tau protein binding; • metal chelating activity; • 脂質輸送体活性; • cholesterol binding; • 抗酸化活性; • identical protein binding; • 脂質結合;
細胞の構成要素	• 細胞質; • 膜; • キロミクロン; • 細胞外領域; • 細胞核; • 細胞外ベシクル; • endocytic vesicle lumen; • very-low-density lipoprotein particle; • 細胞外液; • 小胞体; • エキソソーム; • ゴルジ体; • blood microparticle; • 細胞外マトリックス; • 細胞膜; • neuronal cell body; • early endosome; • low-density lipoprotein particle; • 樹状突起; • high-density lipoprotein particle; • intermediate-density lipoprotein particle;
生物学的プロセス	• negative regulation of neuron apoptotic process; • response to dietary excess; • negative regulation of lipid transport across blood-brain barrier; • 脂質輸送; • positive regulation of lipid biosynthetic process; • regulation of axon extension; • positive regulation of postsynaptic membrane organization; • positive regulation of cholesterol esterification; • phospholipid efflux; • cholesterol catabolic process; • positive regulation of dendritic spine development; • 受容体介在性エンドサイトーシス; • retinoid metabolic process; • positive regulation of amyloid-beta formation; • lipid homeostasis; • lipoprotein biosynthetic process; • cholesterol homeostasis; • negative regulation of inflammatory response; • triglyceride metabolic process; • negative regulation of canonical Wnt signaling pathway; • negative regulation of dendritic spine maintenance; • negative regulation of blood vessel endothelial cell migration; • NMDA glutamate receptor clustering; • 活性酸素への反応; • negative regulation of blood coagulation; • 酸化ストレスへの反応; • positive regulation of nitric-oxide synthase activity; • negative regulation of phospholipid efflux; • positive regulation of cholesterol efflux; • negative regulation of MAP kinase activity; • artery morphogenesis; • very-low-density lipoprotein particle remodeling; • regulation of neuronal synaptic plasticity; • negative regulation of dendritic spine development; • negative regulation of cholesterol biosynthetic process; • positive regulation of dendritic spine maintenance; • positive regulation of phospholipid efflux; • negative regulation of presynaptic membrane organization; • negative regulation of neuron death; • high-density lipoprotein particle clearance; • long-chain fatty acid transport; • lipoprotein metabolic process; • regulation of tau-protein kinase activity; • Gタンパク質共役受容体シグナル伝達経路; • chylomicron remnant clearance; • cellular calcium ion homeostasis; • cholesterol metabolic process; • very-low-density lipoprotein particle clearance; • virion assembly; • negative regulation of lipid biosynthetic process; • cGMP-mediated signaling; • triglyceride catabolic process; • positive regulation of presynaptic membrane organization; • positive regulation of neurofibrillary tangle assembly; • AMPA glutamate receptor clustering; • positive regulation of low-density lipoprotein particle receptor catabolic process; • positive regulation of lipid transport across blood-brain barrier; • fatty acid homeostasis; • nitric oxide mediated signal transduction; • 輸送; • cholesterol efflux; • 遺伝子発現調節; • negative regulation of cholesterol efflux; • regulation of amyloid-beta clearance; • neuron projection regeneration; • negative regulation of postsynaptic membrane organization; • ステロイド代謝プロセス; • regulation of Cdc42 protein signal transduction; • 脂質代謝; • negative regulation of amyloid-beta formation; • positive regulation of membrane protein ectodomain proteolysis; • 血管拡張; • intracellular transport; • synaptic transmission, cholinergic; • positive regulation of neuron death; • high-density lipoprotein particle assembly; • protein import; • high-density lipoprotein particle remodeling; • negative regulation of endothelial cell proliferation; • maintenance of location in cell; • negative regulation of platelet activation; • low-density lipoprotein particle remodeling; • positive regulation by host of viral process; • cytoskeleton organization; • regulation of neuron death; • reverse cholesterol transport; • lipoprotein catabolic process; • triglyceride homeostasis; • cellular oxidant detoxification; • lipid transport involved in lipid storage;
	出典:Amigo / QuickGO
オルソログ
	348
	11816
	ENSG00000130203
	ENSMUSG00000002985
	P02649
	P08226
	NM_001302691; NM_000041; NM_001302688; NM_001302689; NM_001302690
	NM_009696; NM_001305819; NM_001305843; NM_001305844
	NP_000032; NP_001289617; NP_001289618; NP_001289619; NP_001289620
	NP_001292748; NP_001292772; NP_001292773; NP_033826
	ウィキデータ
閲覧/編集ヒト	閲覧/編集マウス

アポリポプロテインE (Apolipoprotein E、APOE) は、脂質の代謝に関与するタンパク質である。APOEは、アポリポタンパク質と呼ばれる脂質結合タンパク質のファミリーに属している。血流の中で、APOEはカイロミクロンレムナント（chylomicron remnant）、超低密度リポタンパク質（VLDL:very low density lipoprotein）、中間密度リポタンパク質（IDL:intermediate-density lipoprotein）や、いくつかの高密度リポタンパク質（HDL:hight density lipoprotein）を含むリポタンパク質粒子の一部として存在している^[5]。APOEはVLDL受容体と相互作用し、これはトリグリセリドが豊富なリポタンパク質の異化に必須である^[6]。

APOEは末梢組織では主に肝臓やマクロファージによって産生され、コレステロールの代謝を仲介する。中枢神経系ではAPOE4は主にアストロサイトによって産生され、低分子量リポタンパク質受容体ファミリーのメンバーであるAPOE受容体を介してコレステロールをニューロンに輸送する^[7]。APOEは、脳におけるコレステロールの主要な運搬役である^[8]。APOEは活性化されたC1qと複合体を形成することで、古典的補体活性化経路のチェックポイントインヒビターとして働く^[9]。

APOEはアルツハイマー病や心血管疾患にも関与している^[10]。

構造[編集]

遺伝子[編集]

APOE遺伝子は19番染色体上にあり、アポリポプロテインC1（APOC1）やアポリポプロテインC2（APOC2）遺伝子とクラスターを形成している。APOE遺伝子は4つのエクソンと3つのイントロンを持ち、全長は3597塩基対である。APOE遺伝子は、コレステロール、脂肪酸、グルコース恒常性の重要な調節因子である肝臓X受容体（liver X receptor）や、肝臓X受容体とヘテロ二量体を形成する核内受容体であるperoxisome proliferator-activated receptor γ（PPARγ）によって転写・活性化される^[11]。メラニン細胞においては、APOE遺伝子の発現は小眼球症関連転写因子（Microphthalmia-associated transcription factor、MITF）によって調節される^[12]。

タンパク質[編集]

APOEは299アミノ酸からなり、複数の両親媒性αヘリックスを持つ。結晶構造解析によると、蝶番領域がN末端とC末端領域を接続している。N末端領域(1-167アミノ酸)は、非極性の側面がタンパク質の内側を向いた逆並行の4ヘリックスバンドルを形成する。一方、C末端ドメイン(206-299アミノ酸)は、3つのαヘリックスを持ち、これが大きな疎水性表面を形成してN末端のヘリックスバンドルと水素結合や塩橋を介して相互作用する。C末端領域は、低密度リポタンパク質受容体（low density lipoprotein receptor、LDLR）結合サイトも持つ^[13]。

遺伝子多型[編集]

APOE遺伝子には主に3つの対立遺伝子（ε2、ε3、ε4^[14]^[15]）がある。3種類の対立遺伝子産物は112番目と158番目のアミノ酸が1つまたは2つ違うだけだが^[16]^[17]^[18]（APOE-ε2 (cys112, cys158), APOE-ε3 (cys112, arg158), and APOE-ε4 (arg112, arg158)^[10]^[19]^[20]）、この違いによりAPOEの構造や機能も変化する。

遺伝子多型	世界における対立遺伝子頻度	疾患との関連
ε2 (rs7412-T, rs429358-T)	8.4%^[21]	APOE2は細胞表面の受容体にあまり結合しないが、E3やE4はよく結合する^[22]。E2はアテローム性動脈硬化リスクの増加と低下の両方に関与している。E2をホモ接合型で持つ人は、摂食した脂質の消費が遅く、若年での心血管疾患や、遺伝的疾患であるIII型高リポタンパク血症のリスクが著しく高くなる（この疾患の患者の94.4%がE2ホモ接合型の人である）。しかし、E2ホモ接合型の人のうちこの疾患を発症するのは2%程度であるため、他の環境的または遺伝的要因（例えば食事中のコレステロールや年齢）も関係していると考えられる^[23]^[24]^[25]。E2はパーキンソン病にも関係しているが^[26]、この発見はより長期の関連研究では再現されていない^[27]。
ε3 (rs7412-C, rs429358-T)	77.9%^[21]	この変異体が、「自然な」APOE遺伝型だと考えられている。
ε4 (rs7412-C, rs429358-C)	13.7%^[21]	E4は、アテローム性動脈硬化、アルツハイマー病^[28]^[29]、認知機能障害^[30]^[31]、海馬の萎縮^[31]、ヒト免疫不全ウイルス^[32]、多発性硬化症の早期進行^[33]^[34]、外傷性脳損傷後の不利な結果^[35]、虚血性脳血管障害^[36]、睡眠時無呼吸^[37]^[38]、テロメアの短縮加速^[39]、神経突起の伸長減少^[40]、COVID-19^[41]に関与している。E2やE3と比較してE4対立遺伝子が持つ顕著な長所としては高レベルのビタミンDと正の関連があり、これがE4が多くの疾患や障害との関連が指摘されるにもかかわらず保有されている説明となるかもしれない^[42]。

保護的に働きうる他の遺伝子多型との相互作用など、APOEのアイソフォームについて研究しなければならないことはまだ多く、よってAPOE多型の影響について決定的な発言をする前に注意が必要である。これは、APOEアイソフォームが認知機能とアルツハイマー病の発症にどのように影響するかに関連して特に必要である。さらに、APOE遺伝子多型が若い年齢層の認知に影響を与えるという証拠は（若いAPOE4年齢層におけるエピソード記憶能力と神経効率の向上の可能性以外）なく、またAPOE4アイソフォームがいかなる感染症に対するリスクを上昇させるという証拠もない^[43]。

機能[編集]

APOEは、脂質や脂溶性ビタミン、コレステロールをリンパ系や血液へと輸送する。APOEは主に肝臓で合成されるが、脳や腎臓、脾臓など他の組織でも見られる^[19]。神経系では、非神経細胞であるアストロサイトやミクログリアが主にAPOEを産生する一方、ニューロンはAPOEに対する受容体を発現する^[44]。哺乳類ではこれまでに7種類のAPO受容体が同定されており、これらは進化的に保存されたLDLRファミリーに属する^[45]。

APOEは、まず始めにリポタンパク質の代謝と心血管疾患における重要性が認識された。APOEに異常が生じると、キロミクロン、VLDL、LDLの除去が障害された結果、血漿中のコレステロールとトリグリセリドが増加し、家族性異常βリポタンパク血症（別名：III型高リポタンパク血症）の原因となる^[6]^[46]。近年では、アルツハイマー病や認知機能、免疫調節など、リポタンパク質の輸送と直接は関係ない生化学的プロセスにおける役割も研究されている^[10]。詳細なメカニズムはまだ不明だが、APOE4が機械的損傷後のカルシウムイオンの増加とアポトーシスに関与していると言われている^[47]。

免疫調節の分野では、炎症や酸化の調節に加え、T細胞の増殖抑制、マクロファージ機能の調節、CD1による^[48]ナチュラルキラーT細胞への脂質抗原提示の促進など多くの免疫プロセスにAPOEは関与している^[49]。 APOEはマクロファージによって産生され、APOEの分泌は末梢血単核細胞の単球に限定されており、その分泌は炎症性サイトカインにより抑制、TGF-βにより促進される^[50]。

臨床的意義[編集]

アルツハイマー病[編集]

E4は、老年期の孤発性アルツハイマー病発症の遺伝的危険因子の中で最もよく知られているものである^[51]。しかし、E4は全ての人々のリスクに関係している訳ではないナイジェリア人は世界の中でAPOE4対立遺伝子の頻度が最も高いが^[52]、アルツハイマー病患者は稀である^[52]^[53]。これは、コレステロールレベルが低いためだと考えられる^[52]^[53]^[54]^[55]。白色人種と日本人の中でE4対立遺伝子をホモ接合型で有している人は、APOE4を持たない人と比べて75歳までにアルツハイマー病になるリスクが10～30倍高くなる。これは、アミロイドβタンパク質との相互作用が原因かもしれない^[56]。アルツハイマー病は、アミロイドβの蓄積が特徴である。アポリポプロテインEは、細胞の中や細胞の間でアミロイドβの分解を促進する。APOE4はこの分解能力が他のアイソフォームより低く、アルツハイマー病に対する脆弱性を高めている^[57]。

アルツハイマー病患者の40–65%が少なくとも1コピーのε4対立遺伝子を持つが、APOE4はアルツハイマー病の決定因子ではない。アルツハイマー病患者の少なくとも3分の1はAPOE4を持っておらず、一方APOE4 ホモ接合型だが発症しない人もいる。しかし、2つのε4対立遺伝子を持つ人は、アルツハイマー病発症のリスクが最大で20倍高くなる^[58]。一方で、APOE2対立遺伝子はアルツハイマー病の抑制に働くかもしれないという証拠もある^[59]。したがって、最もアルツハイマー病の発症リスクが高く、年齢を低下させる遺伝型はAPOE4/4（APOE4のホモ接合型）である。

APOE3/3（APOE3のホモ接合型）という遺伝型を持つ人のアルツハイマー病発症リスクを1.0としたとき、APOE4/4という遺伝型の人のリスクは14.9となる。APOE3/4（APOE3とAPOE4のヘテロ接合型）という人は3.2で、APOE2/4という人は2.6、APOE2/3とAPOE2/2という人は共に0.6となる^[60]。

対立遺伝子	ε2	ε3	ε4
白人におけるAPOE対立遺伝子頻度の推測値^[60]
遺伝型の頻度	8.4%	77.9%	13.7%
アルツハイマー病の頻度	3.9%	59.4%	36.7%

2002年の研究では、ApoE4はアルツハイマー病発症の可能性を著しく増加させることがわかっているが、どのAPOE対立遺伝子の組み合わせを持つ人であっても、中年期における血液中の高い総コレステロールや高血圧は独立した危険因子であり、組み合わさると老年期にアルツハイマー病を発症するリスクを3倍近くに高める^[55]。これらのデータから、血液中のコレステロールを減らすことでアルツハイマー病発症のリスクを減少させることができると考える研究者もおり、ホモ接合型でAPOE4対立遺伝子を持つ人であっても、9～10倍であるアルツハイマー病のリスクを2倍にまで減らせるとしている^[55]。ほとんどの年齢やAPOEの遺伝型で、女性は男性よりアルツハイマー病を発症しやすい。ε4対立遺伝子を持つ女性は、特に男性よりも神経機能障害になりやすい^[61]。

サッカボールをヘディングした後の認知障害[編集]

2020年に発表された研究では、352人の成人のサッカー選手の中で、少なくとも一つのAPOEε4遺伝子を持つ人は、持たない人に比べてヘディングをした後の言語記憶の低下が見られた^[62]。

アテローム性動脈硬化[編集]

アポリポプロテインEの遺伝子をノックアウトしたマウス（APOE^−/−）は、高脂肪食を摂取した際に極度の高コレステロール血症を発症する^[63]。

マラリア[編集]

マウスにマラリアを感染させた際に、APOE^−/−ノックアウトマウスは野生型のマウスに比べて顕著な脳のマラリアの減少と生存の増加を示した^[64]。また、脳におけるT細胞も減少させるが、これは血液脳関門による保護が原因であると思われる^[64]。人間の研究では、APOE2多型はより早期の感染と関係しており、APOE3/4多型は重度のマラリアの可能性を高める^[65]。

相互作用[編集]

相互作用経路図[編集]

以下の遺伝子、タンパク質、代謝はそれぞれの記事をリンクされている ^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|{{{bSize}}}px|alt=スタチン経路図編集]]

スタチン経路図編集

^ この双方向伝達経路地図はWikiPathwaysで編集できる: “Statin_Pathway_WP430”. 2014年5月7日閲覧。

進化[編集]

アポリポタンパク質は、哺乳類に特有のものではなく多くの陸生や海生の脊椎動物にも存在する^[66]。機能の類似したタンパク質は襟鞭毛虫でも見つかっており、全ての動物の出現以前から存在する非常に古いタンパク質であることを示唆している。APOEは、4億年前に魚類と哺乳類が分かれるより前にAPOC-I遺伝子が複製されて生じたと信じられている^[67]。

ヒトの3種類の主要な対立遺伝子であるAPOE4、APOE3、APOE2は、霊長類とヒトが分かれた約750万年前に生じた。これらの対立遺伝子は非同義置換の副産物で、機能に変化が起こった。最初に生じたのはE4である。霊長類とヒトが分かれた後で、ヒトでは4アミノ酸の置換が起こったが、そのうちの3つ（V174L, A18T, A135V）はタンパク質の機能に影響を与えなかった。4つ目の置換であるスレオニンからアルギニンへの置換はタンパク質の機能に変化を与えた。この置換は、同じ置換がデニソワ人のAPOE遺伝子にも見られることから、霊長類とヒトが分かれてからデニソワ人とヒトが分かれるまでの600万年の間のどこかで起こったとされる^[68]。

約22万年前に、APOE4遺伝子の112番目のアルギニンがシステインに置換され、これによりAPOE3対立遺伝子が生じた。最終的に、8万年前に、APOE3の158番目のアルギニンがシステインに置換され、APOE2対立遺伝子が生まれた^[67]^[69]。

出典[編集]

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000130203 - Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000002985 - Ensembl, May 2017
^ Human PubMed Reference:
^ Mouse PubMed Reference:
^ Mahley RW, Weisgraber KH, Huang Y (April 8, 2009). “Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS”. Journal of Lipid Research 50 (Suppl): S183–S188. doi:10.1194/jlr.R800069-JLR200. PMC 2674716. PMID 19106071.
^ ^a ^b “Entrez Gene: APOE apolipoprotein E”. 2020年11月2日閲覧。
^ Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (February 2013). “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy”. Nature Reviews. Neurology 9 (2): 106–18. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.
^ Puglielli L, Tanzi RE, Kovacs DM (April 2003). “Alzheimer's disease: the cholesterol connection” (英語). Nature Neuroscience 6 (4): 345–51. doi:10.1038/nn0403-345. PMID 12658281.
^ Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, ((Megens RTA)), Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, ((Habenicht AJR)) (January 2019). “ApoE attenuates unresolvable inflammation by complex formation with activated C1q” (英語). Nature Medicine 25 (3): 496–506. doi:10.1038/s41591-018-0336-8. PMC 6420126. PMID 30692699.
^ ^a ^b ^c Stolerman, Ian P., ed (2010). Encyclopedia of Psychopharmacology (Online ed.). Berlin: Springer. ISBN 978-3540686989
^ Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P (January 2001). “A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis”. Molecular Cell 7 (1): 161–71. doi:10.1016/S1097-2765(01)00164-2. PMID 11172721.
^ Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (December 2008). “Novel MITF targets identified using a two-step DNA microarray strategy”. Pigment Cell & Melanoma Research 21 (6): 665–76. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971.
^ Phillips MC (September 2014). “Apolipoprotein E isoforms and lipoprotein metabolism”. IUBMB Life 66 (9): 616–23. doi:10.1002/iub.1314. PMID 25328986.
^ Singh PP, Singh M, Mastana SS (2006). “APOE distribution in world populations with new data from India and the UK”. Annals of Human Biology 33 (3): 279–308. doi:10.1080/03014460600594513. PMID 17092867.
^ Eisenberg DT, Kuzawa CW, Hayes MG (September 2010). “Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history”. American Journal of Physical Anthropology 143 (1): 100–11. doi:10.1002/ajpa.21298. PMID 20734437.
^ Online 'Mendelian Inheritance in Man' (OMIM) APOE3 isoform, hyperlipoproteinemia, type III, autosomal recessive -107741#0015
^ Online 'Mendelian Inheritance in Man' (OMIM) APOE3 isoform, APOE, CYS112 and ARG158 -107741#0001
^ Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J (2006). “Variation at APOE and STH loci and Alzheimer's disease”. Behavioral and Brain Functions 2 (1): 13. doi:10.1186/1744-9081-2-13. PMC 1526745. PMID 16603077.
^ ^a ^b Baars, HF; van der Smagt, JJ; Doevandans, PAFM (2011). Clinical Cardiogenetics. London: Springer. ISBN 978-1849964715
^ Ghebranious N, Ivacic L, Mallum J, Dokken C (2005). “Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology”. Nucleic Acids Research 33 (17): e149. doi:10.1093/nar/gni155. PMC 1243648. PMID 16204452.
^ ^a ^b ^c Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013). “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.”. Nat Rev Neurol 9 (2): 106–18. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.
^ Weisgraber KH, Innerarity TL, Mahley RW (March 1982). “Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site”. The Journal of Biological Chemistry 257 (5): 2518–21. PMID 6277903.
^ Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ (November 1982). “Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2”. Journal of Lipid Research 23 (8): 1224–35. PMID 7175379.
^ Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, März W (1998). “Molecular basis of type III hyperlipoproteinemia in Germany”. Human Mutation 11 (6): 417–23. doi:10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.0.CO;2-5. PMID 9603433.
^ Civeira F, Pocoví M, Cenarro A, Casao E, Vilella E, Joven J, González J, Garcia-Otín AL, Ordovás JM (December 1996). “Apo E variants in patients with type III hyperlipoproteinemia”. Atherosclerosis 127 (2): 273–82. doi:10.1016/S0021-9150(96)05969-2. PMID 9125318.
^ Huang X, Chen PC, Poole C (June 2004). “APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease”. Neurology 62 (12): 2198–202. doi:10.1212/01.wnl.0000130159.28215.6a. PMID 15210882.
^ Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB (May 2012). “A large study reveals no association between APOE and Parkinson's disease”. Neurobiology of Disease 46 (2): 389–92. doi:10.1016/j.nbd.2012.02.002. PMC 3323723. PMID 22349451.
^ Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (August 1993). “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families”. Science 261 (5123): 921–23. Bibcode: 1993Sci...261..921C. doi:10.1126/science.8346443. PMID 8346443.
^ Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (March 1993). “Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease”. Proceedings of the National Academy of Sciences of the United States of America 90 (5): 1977–81. Bibcode: 1993PNAS...90.1977S. doi:10.1073/pnas.90.5.1977. PMC 46003. PMID 8446617.
^ Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ (August 2002). “Cognitive change and the APOE epsilon 4 allele”. Nature 418 (6901): 932. doi:10.1038/418932a. hdl:1842/702. PMID 12198535.
^ ^a ^b Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC (November 2004). “Impact of APOE in mild cognitive impairment”. Neurology 63 (10): 1898–901. doi:10.1212/01.wnl.0000144279.21502.b7. PMID 15557508.
^ Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (June 2008). “Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression”. Proceedings of the National Academy of Sciences of the United States of America 105 (25): 8718–23. doi:10.1073/pnas.0803526105. PMC 2438419. PMID 18562290.
^ Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD (February 2001). “APOE genotype is a major predictor of long-term progression of disability in MS”. Neurology 56 (3): 312–16. doi:10.1212/wnl.56.3.312. PMID 11171894.
^ Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines JL (March 2002). “Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis”. American Journal of Human Genetics 70 (3): 708–17. doi:10.1086/339269. PMC 384947. PMID 11836653.
^ Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z (January 1999). “Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury”. Neurology 52 (2): 244–48. doi:10.1212/wnl.52.2.244. PMID 9932938.
^ McCarron MO, Delong D, Alberts MJ (October 1999). “APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis”. Neurology 53 (6): 1308–11. doi:10.1212/wnl.53.6.1308. PMID 10522889.
^ Kadotani H, Kadotani T, Young T, Peppard PE, Finn L, Colrain IM, Murphy GM, Mignot E (June 2001). “Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults”. JAMA 285 (22): 2888–90. doi:10.1001/jama.285.22.2888. PMID 11401610.
^ Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline S, Givelber RJ, Young T (August 2004). “APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study”. Neurology 63 (4): 664–68. doi:10.1212/01.wnl.0000134671.99649.32. PMID 15326239.
^ Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL (February 2013). “Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use”. PLOS ONE 8 (2): e54713. doi:10.1371/journal.pone.0054713. PMC 3572118. PMID 23418430.
^ Raber J (May 2008). “AR, apoE, and cognitive function”. Hormones and Behavior 53 (5): 706–15. doi:10.1016/j.yhbeh.2008.02.012. PMC 2409114. PMID 18395206.
^ Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D (October 2020). “APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort” (英語). The Journals of Gerontology: Series A 75 (11): 2231–2232. doi:10.1093/gerona/glaa131. ISSN 1079-5006. PMC 7314139. PMID 32451547.
^ Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, Egert S, Müller MJ, Schreiber S, Nöthlings U, Rimbach G (September 2011). “APOE ε4 is associated with higher vitamin D levels in targeted replacement mice and humans”. FASEB Journal 25 (9): 3262–70. doi:10.1096/fj.11-180935. PMID 21659554.
^ Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, Boesiger P, Hock C, Nitsch RM, Papassotiropoulos A, Henke K (August 2007). “Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers”. Cerebral Cortex 17 (8): 1934–47. doi:10.1093/cercor/bhl103. PMID 17077159.
^ Zhang Z, Mu J, Li J, Li W, Song J (January 2013). “Aberrant apolipoprotein E expression and cognitive dysfunction in patients with poststroke depression”. Genetic Testing and Molecular Biomarkers 17 (1): 47–51. doi:10.1089/gtmb.2012.0253. PMC 3525887. PMID 23171142.
^ Rogers JT, Weeber EJ (August 2008). “Reelin and apoE actions on signal transduction, synaptic function and memory formation”. Neuron Glia Biology 4 (3): 259–70. doi:10.1017/S1740925X09990184. PMID 19674510.
^ Sacks FM (February 2015). “The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia”. Current Opinion in Lipidology 26 (1): 56–63. doi:10.1097/MOL.0000000000000146. PMC 4371603. PMID 25551803.
^ Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X (Aug 2015). “Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury”. Neuroscience 301: 375–83. doi:10.1016/j.neuroscience.2015.06.005. PMID 26073697.
^ van den Elzen P, Garg S, León L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB (October 2005). “Apolipoprotein-mediated pathways of lipid antigen presentation”. Nature 437 (7060): 906–10. Bibcode: 2005Natur.437..906E. doi:10.1038/nature04001. PMID 16208376.
^ Zhang HL, Wu J, Zhu J (2010). “The role of apolipoprotein E in Guillain–Barré syndrome and experimental autoimmune neuritis”. Journal of Biomedicine & Biotechnology 2010 ( ): 357412. doi:10.1155/2010/357412. PMC 2825561. PMID 20182542.
^ Braesch-Andersen S, Paulie S, Smedman C, Mia S, Kumagai-Braesch M (2013). “ApoE production in human monocytes and its regulation by inflammatory cytokines”. PLOS ONE 8 (11): e79908. Bibcode: 2013PLoSO...879908B. doi:10.1371/journal.pone.0079908. PMC 3828220. PMID 24244577.
^ Sadigh-Eteghad S, Talebi M, Farhoudi M (October 2012). “Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis”. Neurosciences 17 (4): 321–26. PMID 23022896.
^ ^a ^b ^c Sepehrnia B, Kamboh MI, Adams-Campbell LL, Bunker CH, Nwankwo M, Majumder PP, Ferrell RE (October 1989). “Genetic studies of human apolipoproteins. X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks”. American Journal of Human Genetics 45 (4): 586–91. PMC 1683508. PMID 2491016.
^ ^a ^b Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A (1998-01-01). “Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease”. Neuroepidemiology 17 (1): 14–20. doi:10.1159/000026149. PMID 9549720.
^ Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M (2003-01-01). “Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol”. Journal of Molecular Neuroscience 20 (3): 395–406. doi:10.1385/JMN:20:3:395. PMID 14501024.
^ ^a ^b ^c Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (August 2002). “Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease”. Annals of Internal Medicine 137 (3): 149–55. doi:10.7326/0003-4819-137-3-200208060-00006. PMID 12160362.
^ Wisniewski T, Frangione B (February 1992). “Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid”. Neuroscience Letters 135 (2): 235–38. doi:10.1016/0304-3940(92)90444-C. PMID 1625800.
^ Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (June 2008). “ApoE promotes the proteolytic degradation of Abeta”. Neuron (Cell Press) 58 (5): 681–93. doi:10.1016/j.neuron.2008.04.010. PMC 2493297. PMID 18549781 (2008-06-13).
^ Hauser PS, Ryan RO (October 2013). “Impact of apolipoprotein E on Alzheimer's disease”. Current Alzheimer Research 10 (8): 809–17. doi:10.2174/15672050113109990156. PMC 3995977. PMID 23919769.
^ Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE (June 1994). “Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease”. Nature Genetics 7 (2): 180–84. doi:10.1038/ng0694-180. PMID 7920638.
^ ^a ^b Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997). “Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium”. JAMA 278 (16): 1349–56. doi:10.1001/jama.1997.03550160069041. PMID 9343467.
^ Damoiseaux, Jessica S.; Seeley, William W.; Zhou, Juan; Shirer, William R.; Coppola, Giovanni; Karydas, Anna; Rosen, Howard J.; Miller, Bruce L. et al. (2012-06-13). “Gender Modulates the APOE ε4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels” (英語). Journal of Neuroscience 32 (24): 8254–62. doi:10.1523/JNEUROSCI.0305-12.2012. ISSN 0270-6474. PMC 3394933. PMID 22699906.
^ Hunter LE, Freudenberg-Hua Yun, Davies P, Kim M, Lipton RB, Stewart WF, Srinivasan P, Hu S, Lipton ML (2020-04-01). “Associations of Apolipoprotein E ε4 Genotype and Ball Heading With Verbal Memory in Amateur Soccer Players” (英語). JAMA Neurology 77 (4): 419. doi:10.1001/jamaneurol.2019.4828. ISSN 2168-6149. PMC 6990972. PMID 31985774.
^ McNeill E, Channon KM, Greaves DR (June 2010). “Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications”. Clinical Science 118 (11): 641–55. doi:10.1042/CS20090488. PMID 20210786.
^ ^a ^b Kassa FA, Van Den Ham K, Rainone A, Fournier S, Boilard E, Olivier M (September 2016). “Absence of apolipoprotein E protects mice from cerebral malaria”. Scientific Reports 6 ( ): 33615. Bibcode: 2016NatSR...633615K. doi:10.1038/srep33615. PMC 5028887. PMID 27647324.
^ Wozniak MA, Riley EM, Itzhaki RF (March 2004). "Apolipoprotein E polymorphisms and risk of malaria". Journal of Medical Genetics. 41 (3): 145–46. doi:10.1136/jmg.2003.014613. PMC 1735716. PMID 14985370。
^ Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B (1997). “Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development”. PNAS 94 (16): 8622–27. Bibcode: 1997PNAS...94.8622B. doi:10.1073/pnas.94.16.8622. PMC 23048. PMID 9238027.
^ ^a ^b Huebbe P, Rimbach G (2017). “Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors”. Ageing Research Reviews 37: 146–61. doi:10.1016/j.arr.2017.06.002. PMID 28647612.
^ McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, Fontenot MB, Bradley BJ (2012). “The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes)”. PLOS ONE 7 (10): e47760. Bibcode: 2012PLoSO...747760M. doi:10.1371/journal.pone.0047760. PMC 3480407. PMID 23112842.
^ Finch CE, Stanford CB (2004). “Meat-adaptive genes and the evolution of slower aging in humans”. The Quarterly Review of Biology 79 (1): 3–50. doi:10.1086/381662. PMID 15101252.

参考文献[編集]

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (February 2013). “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy”. Nature Reviews. Neurology 9 (2): 106–18. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.
Gunzburg MJ, Perugini MA, Howlett GJ (December 2007). “Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E”. The Journal of Biological Chemistry 282 (49): 35831–41. doi:10.1074/jbc.M706425200. PMID 17916554.
Kolovou GD, Anagnostopoulou KK (August 2007). “Apolipoprotein E polymorphism, age and coronary heart disease”. Ageing Research Reviews 6 (2): 94–108. doi:10.1016/j.arr.2006.11.001. PMID 17224309.
Lambert JC, Amouyel P (August 2007). “Genetic heterogeneity of Alzheimer's disease: complexity and advances”. Psychoneuroendocrinology 32 (Suppl 1): S62–70. doi:10.1016/j.psyneuen.2007.05.015. PMID 17659844.
Raber J (2007). “Role of apolipoprotein E in anxiety”. Neural Plasticity 2007 ( ): 91236. doi:10.1155/2007/91236. PMC 1940061. PMID 17710250.
Ye J (August 2007). “Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus”. PLOS Pathogens 3 (8): e108. doi:10.1371/journal.ppat.0030108. PMC 1959368. PMID 17784784.
Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J (September 2007). “Association of apolipoprotein E genotypes with lipid levels and coronary risk”. JAMA 298 (11): 1300–11. doi:10.1001/jama.298.11.1300. PMID 17878422.
Itzhaki RF, Dobson CB, Shipley SJ, Wozniak MA (June 2004). “The role of viruses and of APOE in dementia”. Annals of the New York Academy of Sciences 1019 (1): 15–18. Bibcode: 2004NYASA1019...15I. doi:10.1196/annals.1297.003. PMID 15246985.
Ashford JW (2004). “APOE genotype effects on Alzheimer's disease onset and epidemiology”. Journal of Molecular Neuroscience 23 (3): 157–65. doi:10.1385/JMN:23:3:157. PMID 15181244.
Huang Y, Weisgraber KH, Mucke L, Mahley RW (2004). “Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease”. Journal of Molecular Neuroscience 23 (3): 189–204. doi:10.1385/JMN:23:3:189. PMID 15181247.
Masterman T, Hillert J (June 2004). “The telltale scan: APOE epsilon4 in multiple sclerosis”. The Lancet. Neurology 3 (6): 331. doi:10.1016/S1474-4422(04)00763-X. PMID 15157846.
Bocksch L, Stephens T, Lucas A, Singh B (December 2001). “Apolipoprotein E: possible therapeutic target for atherosclerosis”. Current Drug Targets. Cardiovascular & Haematological Disorders 1 (2): 93–106. doi:10.2174/1568006013337944. PMID 12769659.
Mahley RW, Rall SC (2002). “Apolipoprotein E: far more than a lipid transport protein”. Annual Review of Genomics and Human Genetics 1 (1): 507–37. doi:10.1146/annurev.genom.1.1.507. PMID 11701639.
Parasuraman R, Greenwood PM, Sunderland T (April 2002). “The apolipoprotein E gene, attention, and brain function”. Neuropsychology 16 (2): 254–74. doi:10.1037/0894-4105.16.2.254. PMC 1350934. PMID 11949718.
Mahley RW, Ji ZS (January 1999). “Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E”. Journal of Lipid Research 40 (1): 1–16. PMID 9869645.
Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J (July 1998). “The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease”. Brain Research. Brain Research Reviews 27 (2): 119–42. doi:10.1016/S0165-0173(98)00008-3. PMID 9622609.
Roses AD, Einstein G, Gilbert J, Goedert M, Han SH, Huang D, Hulette C, Masliah E, Pericak-Vance MA, Saunders AM, Schmechel DE, Strittmatter WJ, Weisgraber KH, Xi PT (January 1996). “Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism”. Annals of the New York Academy of Sciences 777 (1): 146–57. Bibcode: 1996NYASA.777..146R. doi:10.1111/j.1749-6632.1996.tb34413.x. PMID 8624078.
Strittmatter WJ, Roses AD (May 1995). “Apolipoprotein E and Alzheimer disease”. Proceedings of the National Academy of Sciences of the United States of America 92 (11): 4725–27. Bibcode: 1995PNAS...92.4725S. doi:10.1073/pnas.92.11.4725. PMC 41779. PMID 7761390.
de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM (1995). “Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels”. Human Mutation 4 (3): 178–94. doi:10.1002/humu.1380040303. PMID 7833947.
Moriyama K, Sasaki J, Matsunaga A, Arakawa F, Takada Y, Araki K, Kaneko S, Arakawa K (September 1992). “Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia”. Biochimica et Biophysica Acta 1128 (1): 58–64. doi:10.1016/0005-2760(92)90257-V. PMID 1356443.
Mahley RW (April 1988). “Apolipoprotein E: cholesterol transport protein with expanding role in cell biology”. Science 240 (4852): 622–30. Bibcode: 1988Sci...240..622M. doi:10.1126/science.3283935. PMID 3283935.
Utermann G, Pruin N, Steinmetz A (January 1979). “Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man”. Clinical Genetics 15 (1): 63–72. doi:10.1111/j.1399-0004.1979.tb02028.x. PMID 759055.

外部リンク[編集]

Apolipoproteins E - MeSH・アメリカ国立医学図書館・生命科学用語シソーラス（英語）
apoe4.info - APOE-ε4保有者のためのウェブサイト
Human APOE genome location and APOE gene details page in the UCSC Genome Browser.
Overview of all the structural information available in the PDB for UniProt: P02649 (Apolipoprotein E) at the PDBe-KB.

[WikiPathways-66] この双方向伝達経路地図はWikiPathwaysで編集できる: “Statin_Pathway_WP430”. 2014年5月7日閲覧。

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000130203 - Ensembl, May 2017

[refGRCm38Ensembl-2] GRCm38: Ensembl release 89: ENSMUSG00000002985 - Ensembl, May 2017

[3] Human PubMed Reference:

[4] Mouse PubMed Reference:

[5] Mahley RW, Weisgraber KH, Huang Y (April 8, 2009). “Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS”. Journal of Lipid Research 50 (Suppl): S183–S188. doi:10.1194/jlr.R800069-JLR200. PMC 2674716. PMID 19106071.

[entrez-6] “Entrez Gene: APOE apolipoprotein E”. 2020年11月2日閲覧。

[7] Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (February 2013). “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy”. Nature Reviews. Neurology 9 (2): 106–18. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.

[8] Puglielli L, Tanzi RE, Kovacs DM (April 2003). “Alzheimer's disease: the cholesterol connection” (英語). Nature Neuroscience 6 (4): 345–51. doi:10.1038/nn0403-345. PMID 12658281.

[9] Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, ((Megens RTA)), Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, ((Habenicht AJR)) (January 2019). “ApoE attenuates unresolvable inflammation by complex formation with activated C1q” (英語). Nature Medicine 25 (3): 496–506. doi:10.1038/s41591-018-0336-8. PMC 6420126. PMID 30692699.

[encyclopedia-10] Stolerman, Ian P., ed (2010). Encyclopedia of Psychopharmacology (Online ed.). Berlin: Springer. ISBN 978-3540686989

[pmid11172721-11] Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P (January 2001). “A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis”. Molecular Cell 7 (1): 161–71. doi:10.1016/S1097-2765(01)00164-2. PMID 11172721.

[pmid19067971-12] Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (December 2008). “Novel MITF targets identified using a two-step DNA microarray strategy”. Pigment Cell & Melanoma Research 21 (6): 665–76. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971.

[pmid25328986-13] Phillips MC (September 2014). “Apolipoprotein E isoforms and lipoprotein metabolism”. IUBMB Life 66 (9): 616–23. doi:10.1002/iub.1314. PMID 25328986.

[pmid17092867-14] Singh PP, Singh M, Mastana SS (2006). “APOE distribution in world populations with new data from India and the UK”. Annals of Human Biology 33 (3): 279–308. doi:10.1080/03014460600594513. PMID 17092867.

[10.1002/ajpa.21298-15] Eisenberg DT, Kuzawa CW, Hayes MG (September 2010). “Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history”. American Journal of Physical Anthropology 143 (1): 100–11. doi:10.1002/ajpa.21298. PMID 20734437.

[16] Online 'Mendelian Inheritance in Man' (OMIM) APOE3 isoform, hyperlipoproteinemia, type III, autosomal recessive -107741#0015

[17] Online 'Mendelian Inheritance in Man' (OMIM) APOE3 isoform, APOE, CYS112 and ARG158 -107741#0001

[pmid16603077-18] Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J (2006). “Variation at APOE and STH loci and Alzheimer's disease”. Behavioral and Brain Functions 2 (1): 13. doi:10.1186/1744-9081-2-13. PMC 1526745. PMID 16603077.

[cardiogenetics-19] Baars, HF; van der Smagt, JJ; Doevandans, PAFM (2011). Clinical Cardiogenetics. London: Springer. ISBN 978-1849964715

[20] Ghebranious N, Ivacic L, Mallum J, Dokken C (2005). “Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology”. Nucleic Acids Research 33 (17): e149. doi:10.1093/nar/gni155. PMC 1243648. PMID 16204452.

[Liu2013-21] Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013). “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.”. Nat Rev Neurol 9 (2): 106–18. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.

[22] Weisgraber KH, Innerarity TL, Mahley RW (March 1982). “Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site”. The Journal of Biological Chemistry 257 (5): 2518–21. PMID 6277903.

[23] Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ (November 1982). “Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2”. Journal of Lipid Research 23 (8): 1224–35. PMID 7175379.

[24] Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, März W (1998). “Molecular basis of type III hyperlipoproteinemia in Germany”. Human Mutation 11 (6): 417–23. doi:10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.0.CO;2-5. PMID 9603433.

[25] Civeira F, Pocoví M, Cenarro A, Casao E, Vilella E, Joven J, González J, Garcia-Otín AL, Ordovás JM (December 1996). “Apo E variants in patients with type III hyperlipoproteinemia”. Atherosclerosis 127 (2): 273–82. doi:10.1016/S0021-9150(96)05969-2. PMID 9125318.

[26] Huang X, Chen PC, Poole C (June 2004). “APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease”. Neurology 62 (12): 2198–202. doi:10.1212/01.wnl.0000130159.28215.6a. PMID 15210882.

[27] Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB (May 2012). “A large study reveals no association between APOE and Parkinson's disease”. Neurobiology of Disease 46 (2): 389–92. doi:10.1016/j.nbd.2012.02.002. PMC 3323723. PMID 22349451.

[pmid8346443-28] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (August 1993). “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families”. Science 261 (5123): 921–23. Bibcode: 1993Sci...261..921C. doi:10.1126/science.8346443. PMID 8346443.

[pmid8446617-29] Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (March 1993). “Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease”. Proceedings of the National Academy of Sciences of the United States of America 90 (5): 1977–81. Bibcode: 1993PNAS...90.1977S. doi:10.1073/pnas.90.5.1977. PMC 46003. PMID 8446617.

[30] Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ (August 2002). “Cognitive change and the APOE epsilon 4 allele”. Nature 418 (6901): 932. doi:10.1038/418932a. hdl:1842/702. PMID 12198535.

[Cognitive_Impairment-31] Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC (November 2004). “Impact of APOE in mild cognitive impairment”. Neurology 63 (10): 1898–901. doi:10.1212/01.wnl.0000144279.21502.b7. PMID 15557508.

[32] Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (June 2008). “Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression”. Proceedings of the National Academy of Sciences of the United States of America 105 (25): 8718–23. doi:10.1073/pnas.0803526105. PMC 2438419. PMID 18562290.

[33] Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD (February 2001). “APOE genotype is a major predictor of long-term progression of disability in MS”. Neurology 56 (3): 312–16. doi:10.1212/wnl.56.3.312. PMID 11171894.

[34] Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines JL (March 2002). “Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis”. American Journal of Human Genetics 70 (3): 708–17. doi:10.1086/339269. PMC 384947. PMID 11836653.

[35] Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z (January 1999). “Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury”. Neurology 52 (2): 244–48. doi:10.1212/wnl.52.2.244. PMID 9932938.

[36] McCarron MO, Delong D, Alberts MJ (October 1999). “APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis”. Neurology 53 (6): 1308–11. doi:10.1212/wnl.53.6.1308. PMID 10522889.

[37] Kadotani H, Kadotani T, Young T, Peppard PE, Finn L, Colrain IM, Murphy GM, Mignot E (June 2001). “Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults”. JAMA 285 (22): 2888–90. doi:10.1001/jama.285.22.2888. PMID 11401610.

[38] Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline S, Givelber RJ, Young T (August 2004). “APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study”. Neurology 63 (4): 664–68. doi:10.1212/01.wnl.0000134671.99649.32. PMID 15326239.

[pmid23418430-39] Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL (February 2013). “Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use”. PLOS ONE 8 (2): e54713. doi:10.1371/journal.pone.0054713. PMC 3572118. PMID 23418430.

[pmid18395206-40] Raber J (May 2008). “AR, apoE, and cognitive function”. Hormones and Behavior 53 (5): 706–15. doi:10.1016/j.yhbeh.2008.02.012. PMC 2409114. PMID 18395206.

[41] Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D (October 2020). “APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort” (英語). The Journals of Gerontology: Series A 75 (11): 2231–2232. doi:10.1093/gerona/glaa131. ISSN 1079-5006. PMC 7314139. PMID 32451547.

[pmid-21659554-42] Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, Egert S, Müller MJ, Schreiber S, Nöthlings U, Rimbach G (September 2011). “APOE ε4 is associated with higher vitamin D levels in targeted replacement mice and humans”. FASEB Journal 25 (9): 3262–70. doi:10.1096/fj.11-180935. PMID 21659554.

[43] Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, Boesiger P, Hock C, Nitsch RM, Papassotiropoulos A, Henke K (August 2007). “Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers”. Cerebral Cortex 17 (8): 1934–47. doi:10.1093/cercor/bhl103. PMID 17077159.

[44] Zhang Z, Mu J, Li J, Li W, Song J (January 2013). “Aberrant apolipoprotein E expression and cognitive dysfunction in patients with poststroke depression”. Genetic Testing and Molecular Biomarkers 17 (1): 47–51. doi:10.1089/gtmb.2012.0253. PMC 3525887. PMID 23171142.

[45] Rogers JT, Weeber EJ (August 2008). “Reelin and apoE actions on signal transduction, synaptic function and memory formation”. Neuron Glia Biology 4 (3): 259–70. doi:10.1017/S1740925X09990184. PMID 19674510.

[Sacks_2015-46] Sacks FM (February 2015). “The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia”. Current Opinion in Lipidology 26 (1): 56–63. doi:10.1097/MOL.0000000000000146. PMC 4371603. PMID 25551803.

[47] Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X (Aug 2015). “Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury”. Neuroscience 301: 375–83. doi:10.1016/j.neuroscience.2015.06.005. PMID 26073697.

[48] van den Elzen P, Garg S, León L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB (October 2005). “Apolipoprotein-mediated pathways of lipid antigen presentation”. Nature 437 (7060): 906–10. Bibcode: 2005Natur.437..906E. doi:10.1038/nature04001. PMID 16208376.

[pmid20182542-49] Zhang HL, Wu J, Zhu J (2010). “The role of apolipoprotein E in Guillain–Barré syndrome and experimental autoimmune neuritis”. Journal of Biomedicine & Biotechnology 2010 ( ): 357412. doi:10.1155/2010/357412. PMC 2825561. PMID 20182542.

[pmid24244577-50] Braesch-Andersen S, Paulie S, Smedman C, Mia S, Kumagai-Braesch M (2013). “ApoE production in human monocytes and its regulation by inflammatory cytokines”. PLOS ONE 8 (11): e79908. Bibcode: 2013PLoSO...879908B. doi:10.1371/journal.pone.0079908. PMC 3828220. PMID 24244577.

[51] Sadigh-Eteghad S, Talebi M, Farhoudi M (October 2012). “Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis”. Neurosciences 17 (4): 321–26. PMID 23022896.

[:0-52] Sepehrnia B, Kamboh MI, Adams-Campbell LL, Bunker CH, Nwankwo M, Majumder PP, Ferrell RE (October 1989). “Genetic studies of human apolipoproteins. X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks”. American Journal of Human Genetics 45 (4): 586–91. PMC 1683508. PMID 2491016.

[:1-53] Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A (1998-01-01). “Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease”. Neuroepidemiology 17 (1): 14–20. doi:10.1159/000026149. PMID 9549720.

[54] Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M (2003-01-01). “Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol”. Journal of Molecular Neuroscience 20 (3): 395–406. doi:10.1385/JMN:20:3:395. PMID 14501024.

[:2-55] Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (August 2002). “Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease”. Annals of Internal Medicine 137 (3): 149–55. doi:10.7326/0003-4819-137-3-200208060-00006. PMID 12160362.

[pmid1625800-56] Wisniewski T, Frangione B (February 1992). “Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid”. Neuroscience Letters 135 (2): 235–38. doi:10.1016/0304-3940(92)90444-C. PMID 1625800.

[Neuron-57] Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (June 2008). “ApoE promotes the proteolytic degradation of Abeta”. Neuron (Cell Press) 58 (5): 681–93. doi:10.1016/j.neuron.2008.04.010. PMC 2493297. PMID 18549781 (2008-06-13).

[HauserRyan2013-58] Hauser PS, Ryan RO (October 2013). “Impact of apolipoprotein E on Alzheimer's disease”. Current Alzheimer Research 10 (8): 809–17. doi:10.2174/15672050113109990156. PMC 3995977. PMID 23919769.

[pmid7920638-59] Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE (June 1994). “Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease”. Nature Genetics 7 (2): 180–84. doi:10.1038/ng0694-180. PMID 7920638.

[Farrer1997-60] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997). “Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium”. JAMA 278 (16): 1349–56. doi:10.1001/jama.1997.03550160069041. PMID 9343467.

[61] Damoiseaux, Jessica S.; Seeley, William W.; Zhou, Juan; Shirer, William R.; Coppola, Giovanni; Karydas, Anna; Rosen, Howard J.; Miller, Bruce L. et al. (2012-06-13). “Gender Modulates the APOE ε4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels” (英語). Journal of Neuroscience 32 (24): 8254–62. doi:10.1523/JNEUROSCI.0305-12.2012. ISSN 0270-6474. PMC 3394933. PMID 22699906.

[jama-62] Hunter LE, Freudenberg-Hua Yun, Davies P, Kim M, Lipton RB, Stewart WF, Srinivasan P, Hu S, Lipton ML (2020-04-01). “Associations of Apolipoprotein E ε4 Genotype and Ball Heading With Verbal Memory in Amateur Soccer Players” (英語). JAMA Neurology 77 (4): 419. doi:10.1001/jamaneurol.2019.4828. ISSN 2168-6149. PMC 6990972. PMID 31985774.

[pmid20210786-63] McNeill E, Channon KM, Greaves DR (June 2010). “Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications”. Clinical Science 118 (11): 641–55. doi:10.1042/CS20090488. PMID 20210786.

[pmid27647324-64] Kassa FA, Van Den Ham K, Rainone A, Fournier S, Boilard E, Olivier M (September 2016). “Absence of apolipoprotein E protects mice from cerebral malaria”. Scientific Reports 6 ( ): 33615. Bibcode: 2016NatSR...633615K. doi:10.1038/srep33615. PMC 5028887. PMID 27647324.

[pmid14985370-65] Wozniak MA, Riley EM, Itzhaki RF (March 2004). "Apolipoprotein E polymorphisms and risk of malaria". Journal of Medical Genetics. 41 (3): 145–46. doi:10.1136/jmg.2003.014613. PMC 1735716. PMID 14985370。

[Babin_1997-67] Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B (1997). “Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development”. PNAS 94 (16): 8622–27. Bibcode: 1997PNAS...94.8622B. doi:10.1073/pnas.94.16.8622. PMC 23048. PMID 9238027.

[Huebbe_2017-68] Huebbe P, Rimbach G (2017). “Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors”. Ageing Research Reviews 37: 146–61. doi:10.1016/j.arr.2017.06.002. PMID 28647612.

[McIntosh_2012-69] McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, Fontenot MB, Bradley BJ (2012). “The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes)”. PLOS ONE 7 (10): e47760. Bibcode: 2012PLoSO...747760M. doi:10.1371/journal.pone.0047760. PMC 3480407. PMID 23112842.

[pmid15101252-70] Finch CE, Stanford CB (2004). “Meat-adaptive genes and the evolution of slower aging in humans”. The Quarterly Review of Biology 79 (1): 3–50. doi:10.1086/381662. PMID 15101252.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[§ 1]

[66]

[67]

[68]

[69]